The tweet was deleted by the author.
But we saved everything 🙂.
Twist Bioscience announced that its Comprehensive Viral Research Panel, capable of identifying thousands of viral species, is now available to order. Shares are up 6% on the day at $115.67.
Twist Bioscience announced that its Comprehensive Viral Research Panel is now ready to order. The panel is capable of detecting more than 3,100 viral species, including all four hemorrhagic fever families endemic to the Democratic Republic of the Congo, with tolerance for up to 10% sequence mismatch. The product also features integrated One Codex analysis.
View post on X Loading...
RSI at 67.6 is nearing overbought territory, indicating the advance in Twist Bioscience stock is becoming stretched. The price remains supported above its MA-20, MA-50, and MA-200, which keeps the daily structure bullish. The current move aligns with the broader bullish trend on the chart, with the nearest resistance at the weekly high of $117.98.
Traders should watch for a close above $117.98 to gauge whether buying interest will continue to carry Twist Bioscience stock higher. The main technical cue is that RSI at 67.6 is approaching overbought territory, highlighting that upside may be limited from here. Still, while the recent move reflects a sustained trend upward, over the next five trading days there is more than an 80% probability of further upside and less than a 20% chance of downside, with the price expected to trade between $98.94 and $132.39. A close above the weekly high would confirm buyers are following through, while a drop below $99.29 would show the move is being faded. On the weekly chart the longer-term picture stays firmly constructive.
Earlier, analysts noted that Twist Bioscience maintained a constructive technical outlook supported by a strong trend. The latest product launch and subsequent price gain add a new dimension to the company’s momentum, making the weekly high of $117.98 the immediate level for traders to monitor for confirmation of continued strength.